Xencor reported $-25776000 in EBITDA for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Alnylam Pharmaceuticals ALNY:US $ -181.59M 44.32M
Amgen AMGN:US $ 2792M 549M
Arrowhead Research ARWR:US $ -70306000 114.46M
AstraZeneca AZN:LN 3562M 625M
Biogen BIIB:US $ 1075.7M 401M
Bristol Myers Squibb BMY:US $ 5780M 8M
Epizyme EPZM:US $ -49.63M 0.33M
GlaxoSmithKline GSK:LN 2447M 673M
Johnson & Johnson JNJ:US $ 8036M 1273M
Karyopharm Therapeutics KPTI:US $ -42759000 8.35M
Macrogenics MGNX:US $ -63725000 8.44M
Novartis NOVN:VX SF 4660M 108M
Pfizer PFE:US $ 12921M 1739M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M
Seattle Genetics SGEN:US $ -115.89M 0.06M
Xencor XNCR:US $ -25.78M 54.42M